Ischemia modified albumin is an indicator of oxidative stress in multiple sclerosis

Biochemia Medica

Volumn 24, Issue 3, 2014, Pages 383-389

  Aydin, Ozgur ^a   Ellidag, Hamit Yasar ^b   Eren, Esin ^c   Kurtulus, Fatma ^d   Yaman, Aylin ^d   Yilmaz, Necat ^b  

^a Laboratories of Batman Maternity and Children s Hospital   (Turkey)

^b Central laboratories of Antalya Education and Research Hospital of Ministry of Health   (Turkey)

^c Antalya Public Health Center of Ministry of Health   (Turkey)

^d Neurology clinic of Antalya Education and Research Hospital of Ministry of Health   (Turkey)

Author keywords

Ischemia modified albumin; Multiple sclerosis; Oxidative stress

Indexed keywords

DITHIOTHREITOL; ISCHEMIA MODIFIED ALBUMIN; SERUM ALBUMIN; BIOLOGICAL MARKER; ISCHEMIA-MODIFIED ALBUMIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLOOD SAMPLING; CHEMICAL PARAMETERS; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; QUESTIONNAIRE; SOCIAL STATUS; SPECTROPHOTOMETRY; TOTAL ANTI OXIDATIVE STATUS; TOTAL OXIDATIVE STATUS; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OXIDATIVE STRESS; SERUM ALBUMIN; YOUNG ADULT;

EID: 84908126550     PISSN: 13300962     EISSN: None     Source Type: Journal    
DOI: 10.11613/BM.2014.041     Document Type: Article

References (20)

1. Tullman MJ. Overview of the Epidemiology, Diagnosis, and Disease Progression Associated With Multiple Sclerosis. Am J Manag Care 2013;19(2 Suppl):S15-20.
2. Bagnato F, Hametner S, Yao B, van Gelderen P, Merkle H, Cantor FK, et al. Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain 2011;134:3602-15. http://dx.doi.org/10.1093/brain/ awr278.
3. Hametner S, Wimmer I, Haider L, Pfeifenbring S, Bruck W, Lassmann H. Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 2013;74:848-61. http://dx.doi. org/10.1002/ana.23974.
4. Khalil M, Teunissen C, Langkammer C. Iron and neurodegeneration in multiple sclerosis. Mult Scler Int 2011;2011:606807.
5. Williams R, Buchheit CL, Berman NE, LeVine SM. Pathogenic implications of iron accumulation in multiple sclerosis. J Neurochem 2012;120:7-25. http://dx.doi.org/10.1111/ j.1471-4159.2011.07536.x.
6. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation more stable ABTS radical cation. Clin Biochem 2004;37:277-85. http://dx.doi.org/10.1016/j.clinbiochem.2003.11.015.
7. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38:1103-11. http://dx.doi.org/10.1016/j.clinbiochem.2005.08.008.
8. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia— a preliminary report. Emerg Med J 2000;19:311-5. http://dx.doi.org/10.1016/S0736-4679(00)00255-9.
9. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischemia modified albumin. Heart 2006;92:113-4. http://dx.doi.org/10.1136/hrt.2004.049643.
10. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302. http://dx.doi.org/10.1002/ana.22366.
11. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52. http://dx.doi.org/10.1212/WNL.33.11. 1444.
12. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2009;82:2. http://dx.doi. org/10.1186/1755-8794-2-2.
13. Yilmaz N. Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases. Arch Med Sci 2012;8:138-53. http://dx.doi.org/10.5114/aoms.2012. 27294.
14. Cakmak A, Soker M, Koc A, Erel O. Paraoxonase and arylesterase activity with oxidative status in children with thalassemia major. J Pediatr Hematol Oncol 2009;31:583-7. http://dx.doi.org/10.1097/MPH.0b013e3181acd93d.
15. Kirbas A, Kirbas S, Anlar O, Efe H, Yilmaz A. Serum paraoxonase and arylesterase activity and oxidative status in patients with multiple sclerosis. J Clin Neurosci 2013; 20:1106-9. http://dx.doi.org/10.1016/j.jocn.2012.09.020.
16. Miller E, Walczak A, Saluk J, Ponczek MB, Majsterek I. Oxidative modification of patient’s plasma proteins and its role in pathogenesis of multiple sclerosis. Clin Biochem 2012;45:26-30. http://dx.doi.org/10.1016/j.clinbiochem.2011.09.021.
17. Oliveira SR, Kallaur AP, Simao AN, Morimoto HK, Lopes J, Panis C, et al. Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale. J Neurol Sci 2012;321:49-53. http://dx.doi.org/10.1016/j.jns.2012.07.045.
18. Ortiz GG, Macias-Islas MA, Pacheco-Moises FP, Ramos JA, Sustersik S, Barba EA, et al. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Dis Markers 2009;26:35-39. http://dx.doi.org/10.1155/2009/325847.
19. Ljubisavljevic S, Stojanovic I, Vojinovic S, Stojanov D, Stojanovic S, Cvetkovic T, et al. The patients with clinically isolated syndrome and relapsing remitting multiple sclerosis show different levels of advanced protein oxidation products and total thiol content in plasma and CSF. Neurochem Int 2013;62:988-97. http://dx.doi.org/10.1016/j.neuint.2013.02.025.
20. Fiorini A, Koudriavtseva T, Bucaj E, Coccia R, Foppoli C, Giorgi A, et al. Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. PLoS One 2013;8:e65184. http://dx.doi.org/10.1371/journal.pone.0065184.